Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|March 21, 2025

Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis

Author(s)Lisa Swanson, MD, FAAD, Linda Stein Gold, MD, James Song, MD, FAAD

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Episodes in this series

4 experts are featured in this series.

EP. 1 Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy

4 experts are featured in this series.

EP. 2 Optimizing Disease Control and AAD Guidelines for Systemic Therapies

4 experts are featured in this series.

EP. 3 Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 4 The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis

4 experts are featured in this series.

EP. 5 The Impact of JAK Selectivity in Atopic Dermatitis Treatment

4 experts are featured in this series.

EP. 6 Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis

4 experts are featured in this series.

EP. 7 Navigating the Boxed Warning for the JAK Inhibitor Class

4 experts are featured in this series.

EP. 8 Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis

4 experts are featured in this series.

EP. 9 Laboratory Monitoring with Oral JAK Inhibitors

4 experts are featured in this series.

EP. 10 Differentiating Between JAK Inhibitors in Clinical Practice

4 experts are featured in this series.

EP. 11 Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 12 Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation

4 experts are featured in this series.

EP. 13 Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis

4 experts are featured in this series.

EP. 14 Determining Appropriate Candidates for JAK Inhibitor Therapy

4 experts are featured in this series.

EP. 15 Utility of Head-to-Head Studies in Atopic Dermatitis and Future Research Directions

EP. 16 Advancing Atopic Dermatitis Treatment by Understanding the Role of Multitargeted Therapies

EP. 16 Advancing Atopic Dermatitis Treatment by Understanding the Role of Multitargeted Therapies

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Case 1: Choosing Non-Steroidal Topicals for Intertriginous Psoriasis

ByTina Bhutani-Jacques, MD

July 20th 2026

1 expert is featured in this series

The Ongoing Role of Topical Therapy in Plaque Psoriasis Management

ByTina Bhutani-Jacques, MD

July 20th 2026

2 experts are featured in this series

The Safety of Advanced Topical Therapies in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

2 experts are featured in this series

Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

Setting Expectations: Treatment Timelines, Adherence, and Monitoring in Vitiligo

ByNada Elbuluk, MD, MSc, FAAD,Susan Taylor, MD, FAAD

July 14th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

AI-Assisted Imaging Tracks Success of Low-Fluence QSRL Laser for Melasma